Quantitation of Muscle Mass and Muscle Protein Synthesis Rate: Documenting a Response to Myoblast Transfer

  • Robert C. Griggs
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 280)


The goal of treatment in muscular dystrophy is to provide a favorable effect on the natural history of muscle strength. Such an effect can be produced by improvement in strength, by arrest of progression, or by slowing in the rate of progression. All laboratory measurements which assess muscle histology or electrophysiology, muscle mass, or measure muscle components in serum (e.g. creatine kinase) are indirect and of value in a therapeutic trial only to the extent that they either predict or substantiate a clinical response. If myoblast transfer treatment is to be used, it will be studied initially in one muscle or at most, a small number of individual muscles. There is currently no documented way of establishing a change in the natural history of strength for individual muscles in Duchenne dystrophy. Indirect, laboratory measures of “success” of myoblast transfer treatment applied to individual muscles are therefore of potential importance since they may: (1) predict the ultimate clinical success of the treatment; (2) establish a mechanism of action for myoblast transfer; (3) provide clues as to other approaches which could be combined with myoblast transfer to improve results.


Muscle Mass Muscular Dystrophy Duchenne Dystrophy Muscle Protein Synthesis Duchenne Muscular Dystrophy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Heymsfield, S. B., Arteaga, C., McManus, B. S., Smith, J., Moffitt, S., 1983, Measurements of muscle mass in humans: validity of the 24-hour urinary creatinine method, Am J Clin Nutr, 37: 478.PubMedGoogle Scholar
  2. 2.
    Griggs, R. C., Forbes, G., Moxley, R. T., Herr, B. E., 1983, The assessment of muscle mass in progressive neuromuscular disease, Neurol, 33: 158.CrossRefGoogle Scholar
  3. 3.
    Crim, M. C., Calloway, D. H., Margen, S., 1975, Creatine metabolism in men: urinary creatine and creatinine excretions with creatine feeding, J Nutr, 105: 428.PubMedGoogle Scholar
  4. 4.
    Forbes, G. B., Hursh, J. B., 1963, Age and sex tends in LBM calculated from K measurements: with a note on the theoretical basis for the procedure, Ann NY Acad Sci, 110: 255.PubMedCrossRefGoogle Scholar
  5. 5.
    Brooke, M. H., Fenichel, G. M., Griggs, R. C., et al, 1987, Clinical investigation of Duchenne muscular dystrophy: interesting results in a trial of prednisone, Arch Neurol, 44: 812.PubMedCrossRefGoogle Scholar
  6. 6.
    Mendell, J. R., Moxley, R. T., Griggs, R. C., et al, 1989, Randomized, double-blind six-month trial of prednisone in Duchenne’s muscular dystrophy, N Eng J Med, 320: 1592.CrossRefGoogle Scholar
  7. 7.
    Griggs, R. C., Pandya, S., Moxley, R. T., Forbes, G., et al, 1981, Treatment of myopathic carnitine deficiency - quantitation of response to prednisone and carnitine, Trans Am Neurol Assoc, 106: 199.PubMedGoogle Scholar
  8. 8.
    Griggs, R. C., Kingston, W. J., Herr, B. E., Forbes, G., Moxley, R. T., 1985, Effect of testosterone administration on total body potassium and creatinine excretion in myotonic dystrophy, Neurol, 35: 1035.CrossRefGoogle Scholar
  9. 9.
    Griggs, R. C., Pandya, S., Florence, J. M., Brooke, M. H., et al,1989, Randomized controlled trial of testosterone in myotonic dystrophy. Neurol, 39: 219.Google Scholar
  10. 10.
    Horber, F. F., Scheidegger, J. R., et al, 1985, Evidence that prednisone-induced myopathy is reversed by physical training, J Clin Endocrinol Metab, 61: 83.PubMedCrossRefGoogle Scholar
  11. 11.
    Jozefowicz, R. J., Ceckler, T. L., Flood, D. G., Herr, B. E.,Hawthorne, B. W., Griggs, R. C., 1989, Assessment of regional muscle volume utilizing forearm magnetic resonance imaging, Neurol, 39 (Suppl 1): 134.Google Scholar
  12. 12.
    Halliday, D., McKeran, R. 0., 1975, Measurement of muscle protein synthesis rate from serial muscle biopsies and total body protein rnover in many by continuous intravenous infusion of L-[alphaN]lysine, Clin Sci Molec Med, 49: 581.Google Scholar
  13. 13.
    Nair, K. S., Halliday, D., Griggs, R. C., 1988, Leucine incorporation into mixed skeletal muscle protein in man - its relationship to whole body leucine kinetics and muscle fiber composition, Am J Physiol, 254: E208.PubMedGoogle Scholar
  14. 14.
    Rennie, M. J., Edwards, R. H. T., Halliday, D., et al, 1982, Muscle protein synthesis in man: the effects of feeding and fasting, Clin Sci, 63: 519.PubMedGoogle Scholar
  15. 15.
    Moxley, R. T., 1983, Metabolic studies in muscular dystrophy and their relationship to clinical pathophysiology: A focus upon myotonic dystrophy and Duchenne muscular dystrophy, Seminars Neurol, 3: 308.Google Scholar
  16. 16.
    Griggs, R. C., Rennie, M. J., 1983, Muscle wasting in muscular dystrophy: decreased protein synthesis or increased degradation? Ann Neurol, 13: 125.PubMedCrossRefGoogle Scholar
  17. 17.
    Shengraw, R. E., Stuart, C. A., Prince, M. J., Peters, E. J., Wolfe, R. R. 1988, Insulin responsiveness of protein metabolism in vivo following bedrest in humans, Am J Physiol, 255: E548.Google Scholar
  18. 18.
    Griggs, R. C., Halliday, D., Kingston, W., Moxley, R. T., 1986, Effects of testosterone on muscle protein synthesis in myotonic dystrophy. Ann Neurol, 20: 590.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • Robert C. Griggs
    • 1
  1. 1.School of Medicine and Dentistry Department of NeurologyUniversity of RochesterRochesterUSA

Personalised recommendations